Award Recipient 2022
Christian Moritz, PhD
University Hospital of Saint-Étienne,
Saint-Priest-en-Jarez, France
Revealing the autoantigen repertoire of IVIg responders versus non-responders in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Award Recipient 2021
Jonathan Morena, DO.
The Ohio State University,
Columbus, Ohio (US)
Effects of intravenous immunoglobulin on myeloid cell function in Guillain-Barré syndrome
Award Recipient 2020
Jeremie Martinet, PharmD, PhD
Rouen University Hospital,
Rouen, France
Immunoglobulins for neuromuscular disorders: immunomodulation and myoregeneration by IVIg in immune-mediated necrotising myopathy (myoRIg)
Award Recipient 2019
Luuk Wieske, MD, PhD
Academic Medical Center (AMC)
Amsterdam, the Netherlands
Serum nerve damage biomarkers for disease activity in IVIg treated patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
Award Recipient 2018
Dr. med. Miriam Fichtner
Yale University
New Haven, Connecticut, USA
IVIG influence on pathogenic B cells in myasthenia gravis
Award Recipient 2017
Ruth Huizinga, PhD
Erasmus University Medical Center
Rotterdam, The Netherlands
Effect of IVIg on the B-cell receptor repertoire of patients with the Guillain-Barré syndrome
Award Recipient 2016
Luis Querol, MD, PhD
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
IVIg effects on regulatory B cells in patients with neuroimmune diseases
Award Recipient 2015
Krista Kuitwaard, MD
Albert Schweitzer Hospital
Dordecht, The Netherlands
Genetic biomarkers associated with IVIg treatment response or dependency in CIDP
Award Recipient 2013
Erasmus University Medical Center
Rotterdam, The Netherlands
Fcγ-receptor gene polymorphisms and the pharmacokinetics of immunoglobulin treatment in the Guillain-Barré syndrome
Award Recipient 2012
Heinrich-Heine-University
Düsseldorf, Germany
Immunoglobulins in a new animal model of CIDP – the spontaneous chronic autoimmune neuritis in ICAM-1 deficient NOD mice
Award Recipient 2011
Award Recipient 2010
Award Recipient 2009
France
Role of heme oxygenase-1 (hsp-32) in the anti-inflammatory activity of IVIg